This study investigates the stability, efficacy, and mechanisms of IFN-γ- and sPD-1-overexpressing BMSCs in targeted immunotherapy for lung adenocarcinoma, providing novel methods and insights for clinical tumor prevention and treatment. Here, HOXD13 is linked to lung adenocarcinoma.